Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
- New advice in the last 6 months (1)
- Updated advice in the last 6 months (0)
- In development advice (0)
Set out priority areas for quality improvement in health and social care.
- New quality standards in the last 6 months (0)
- Updated quality standards in the last 6 months (0)
- In development quality standards (0)
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject.
Guidance by programme
Advice by programme
Products being developed or updated
News on this topic
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
Around 5,700 cases of multiple myeloma are diagnosed each year in the UK
Putting guidance into practice
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 3 of 3 shared learning examples for this topic: